Form 8-K

0001171843-20-007628.txt : 20201105 0001171843-20-007628.hdr.sgml : 20201105 20201105071208 ACCESSION NUMBER: 0001171843-20-007628 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20201105 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20201105 DATE AS OF CHANGE: 20201105 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOCRYST PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000882796 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 621413174 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-23186 FILM NUMBER: 201288644 BUSINESS ADDRESS: STREET 1: 4505 EMPEROR BOULEVARD STREET 2: SUITE 200 CITY: DURHAM STATE: NC ZIP: 27703 BUSINESS PHONE: 919-859-1302 MAIL ADDRESS: STREET 1: 4505 EMPEROR BOULEVARD STREET 2: SUITE 200 CITY: DURHAM STATE: NC ZIP: 27703 8-K 1 f8k_110520.htm FORM 8-K Form 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_________________

FORM 8-K

_________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 5, 2020

_______________________________

BioCryst Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

_______________________________

Delaware	000-23186	62-1413174
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

4505 Emperor Blvd., Suite 200

Durham, North Carolina 27703

(Address of Principal Executive Offices) (Zip Code)

(919) 859-1302

(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

_______________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock	BCRX	Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On November 5, 2020, BioCryst Pharmaceuticals, Inc. (the "Company") issued a press release announcing recent corporate developments and its financial results for the quarter ended September 30, 2020, which also referenced a conference call and webcast to discuss these recent corporate developments and financial results. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.

Item 7.01. Regulation FD Disclosure.

The information furnished on Exhibit 99.1 is incorporated by reference under this Item 7.01 as if fully set forth herein.

The information in this Current Report on Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description

99.1		Press release dated November 5, 2020 entitled "BioCryst Reports Third Quarter 2020 Financial Results and Upcoming Key Milestones"
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	BioCryst Pharmaceuticals, Inc.


Date: November 5, 2020	By:	/s/ Alane Barnes
		Alane Barnes
		Senior Vice President and Chief Legal Officer

EX-99.1 2 exh_991.htm PRESS RELEASE EdgarFiling

EXHIBIT 99.1

BioCryst Reports Third Quarter 2020 Financial Results and Upcoming Key Milestones

—ORLADEYO^™ (berotralstat) PDUFA date December 3, 2020—

—Approval decisions expected in Japan in December 2020, EU in early 2021—

RESEARCH TRIANGLE PARK, N.C., Nov. 05, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced financial results for the third quarter ended September 30, 2020, and provided a corporate update.

“We are 28 days from our PDUFA date and we are ready to launch ORLADEYO to bring HAE patients the oral, once-daily medicine they have been waiting for to prevent attacks, reduce their burden of therapy and live a normal life,” said Jon Stonehouse, president and chief executive officer of BioCryst.

“In addition to this commercial transformation of the company, and the revenue it brings, our pipeline of BioCryst-discovered molecules continues to advance, with several upcoming near-term data readouts,” Stonehouse added.

Program Updates and Key Milestones

Hereditary Angioedema (HAE) Program – ORLADEYO: Oral, once-daily treatment for prevention of HAE attacks

BioCryst expects three regulatory approvals for ORLADEYO in Q4 2020 and early 2021.
- The U.S. Food and Drug Administration (FDA) is reviewing a new drug application for ORLADEYO and has set an action date of December 3, 2020, under the Prescription Drug User Fee Act (PDUFA).
- In Japan, ORLADEYO is being reviewed under Sakigake designation. The Pharmaceutical and Medical Devices Agency (PMDA) has confirmed their regulatory review schedule and the company expects a decision on approval in December 2020.
- On March 30, 2020, the company announced that the European Medicines Agency (EMA) had validated its marketing authorization application (MAA) submission for ORLADEYO and begun its formal review of the MAA under the centralized procedure. The company expects an opinion from the Committee for Medicinal Products for Human Use (CHMP) within approximately 12 months from MAA validation.

BioCryst has completed the build-out of the commercial infrastructure to support the successful launch of ORLADEYO in the U.S.
- The company has hired and trained accomplished U.S. rare disease sales and market access teams and has deployed a robust patient services support hub.
- The company is well-positioned in terms of product supply and inventory on-hand to support the launch and anticipated demand for ORLADEYO.
On October 30, 2020, the company announced that the United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA) has granted oral, once-daily berotralstat a positive scientific opinion through the Early Access to Medicines Scheme (EAMS). Under the EAMS, HAE patients in the UK aged 12 years and older can gain access to berotralstat for the routine prevention of recurrent attacks of HAE before the drug is granted marketing authorization by the European Commission. Medicines included in the EAMS are those that have a high unmet need, are intended to treat, diagnose or prevent seriously debilitating or life-threatening conditions where there are no adequate treatment options, and are likely to offer significant advantage over methods currently used in the UK.
On October 28, 2020, the company announced it will present five abstracts and one Distinguished Industry Oral Abstract, including 48-week results from the APeX-2 trial and new data on quality of life and the treatment burden of injectable medication administration, at the upcoming (virtual) Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology on November 13-15.
On October 22, 2020, the company announced that data from the first 24 weeks of the APeX-2 trial of oral, once-daily berotralstat in patients with HAE have been published online by the Journal of Allergy and Clinical Immunology.

Complement Oral Factor D Inhibitor Program – BCX9930

The company is completing an ongoing dose ranging trial in treatment-naïve paroxysmal nocturnal hemoglobinuria (PNH) patients, and PNH patients with an inadequate response to C5 inhibitors.
- Seven treatment-naïve PNH patients are currently receiving BCX9930, with four beyond 12 weeks of therapy, including two with more than 32 weeks on therapy. All seven treatment-naïve patients are continuing to benefit from BCX9930 treatment.
- Based on the excellent results observed to-date at 400 mg bid and 500 mg bid, the company plans to add patients at these dose levels.
- Because the acceleration of COVID-19 in the EU has slowed start-up of the inadequate responder cohorts, the company expects to report data from treatment-naïve and inadequate C5 responders dosed up to 500 mg bid in the first quarter of 2021.
On September 30, 2020, the company announced new data from treatment-naïve (no prior treatment with C5 inhibitors) PNH patients receiving doses of oral BCX9930 through 400 mg bid. Oral BCX9930 is driving rapid and dose-dependent reductions in key biomarkers, including LDH, and increasing hemoglobin levels in all PNH patients in the trial. Increases in hemoglobin levels were maintained without transfusions. BCX9930 has been safe and well tolerated at all doses in the trial. No drug-related serious adverse events have been reported.
On August 31, 2020, the company announced that the FDA has granted Orphan Drug designation for BCX9930, for the treatment of PNH. Orphan Drug designation qualifies BCX9930 for various development incentives, including tax credits for certain clinical costs, a waiver of the new drug application fee and a designated period of market exclusivity following approval.

Coronavirus Antiviral Program – Galidesivir (BCX4430)

Part 1 of a clinical trial of galidesivir in COVID-19 patients in Brazil has completed enrollment and the company expects to report results in the fourth quarter.
The primary endpoint of part 1 is safety. Data is also being collected on secondary endpoints, including clinical outcomes and virology. Based on recent conversations with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, the major funding partner for the program, the company understands that data from part 1 is a gating item for the program and some evidence of clinical and/or antiviral activity is important for the program to advance.

Additional Updates

The company remains on track to report data in Q4 2020 from its ongoing Phase 1 clinical trial of BCX9250, an oral ALK-2 kinase inhibitor for treatment of fibrodysplasia ossificans progressiva (FOP), in healthy subjects.
On September 3, 2020, the company announced that the U.S. Department of Health and Human Services (HHS) has exercised its option to purchase an additional 10,000 doses of BioCryst’s approved antiviral influenza therapy, RAPIVAB^® (peramivir injection), for approximately $7 million. The order is part of a $34.7 million contract (Contract No. 75D301-18-C-02984) the Centers for Disease Control and Prevention awarded in 2018 for the procurement of up to 50,000 doses of RAPIVAB^® (peramivir injection) over a five-year period for the strategic national stockpile.

Third Quarter 2020 Financial Results

For the three months ended September 30, 2020, total revenues were $6.1 million, compared to $1.8 million in the third quarter of 2019. The increase was primarily due to an increase in collaboration revenue under U.S. government development contracts and higher peramivir product sales to our commercial partners.

Research and development (R&D) expenses for the third quarter of 2020 increased to $30.2 million from $25.1 million in the third quarter of 2019, primarily due to increased spending on our complement-mediated diseases and galidesivir programs.

Selling, general and administrative (SG&A) expenses for the third quarter of 2020 increased to $17.2 million, compared to $11.7 million in the third quarter of 2019. The increase was primarily due to increased spending on commercial and medical affairs activities to support the U.S. commercial launch of ORLADEYO.

Interest expense was $2.9 million in the third quarter of 2020, compared to $3.0 million in the third quarter of 2019.

Net loss for the third quarter of 2020 was $46.1 million, or $0.26 per share, compared to a net loss of $37.6 million, or $0.34 per share, for the third quarter of 2019.

Cash, cash equivalents, restricted cash and investments totaled $148.5 million at September 30, 2020, and reflect an increase from $137.8 million at December 31, 2019. Operating cash use for the third quarter of 2020 was $43.1 million. Net operating cash use for the first nine months of 2020 was $98.0 million, as compared to $77.9 million for the first nine months of 2019.

Financial Outlook for 2020

BioCryst continues to expect full year 2020 net operating cash use to be in the range of $150 to $165 million, and its operating expenses to be in the range of $180 to $195 million. The company’s operating expense range excludes equity-based compensation expense due to the difficulty in reliably projecting this expense, as it is impacted by the volatility and price of the company’s stock, as well as by the vesting of the company’s outstanding performance-based stock options.

Conference Call and Webcast

BioCryst management will host a conference call and webcast at 8:30 a.m. ET today to discuss the financial results and provide a corporate update. The live call may be accessed by dialing 877-303-8027 for domestic callers and 760-536-5165 for international callers and using conference ID # 3766784. A live webcast of the call and any slides will be available online at the investors section of the company website at www.biocryst.com. A telephone replay of the call will be available by dialing 855-859-2056 for domestic callers or 404-537-3406 for international callers and entering the conference ID # 3766784.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. BioCryst has several ongoing development programs including ORLADEYO^™ (berotralstat), an oral treatment for hereditary angioedema, BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, galidesivir, a potential treatment for COVID-19, Marburg virus disease and Yellow Fever, and BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva. RAPIVAB^® (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, is BioCryst's first approved product and has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan, Korea and the European Union. Post-marketing commitments for RAPIVAB are ongoing. For more information, please visit the Company's website at www.BioCryst.com.

Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding future results, performance or achievements. These statements are identified by use of terms such as “expect,” “plan,” “anticipate,” “will,” “may,” “project,” and similar words, although some forward-looking statements may be expressed differently. These statements involve known and unknown risks, uncertainties and other factors which may cause BioCryst’s actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and are subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include: the ongoing COVID-19 pandemic, which could create challenges in all aspects of BioCryst’s business, including without limitation delays, stoppages, difficulties and increased expenses with respect to BioCryst’s and its partners’ development, regulatory processes and supply chains, negatively impact BioCryst’s ability to access the capital or credit markets to finance its operations, or have the effect of heightening many of the risks described below or in the documents BioCryst files periodically with the Securities and Exchange Commission; developing and commercializing ORLADEYO or any HAE product candidate may take longer or may be more expensive than planned; ongoing and future preclinical and clinical development of BCX9930, BCX9250 and galidesivir may not have positive results; BioCryst may not be able to enroll the required number of subjects in planned clinical trials of product candidates; BioCryst may not advance human clinical trials with product candidates as expected; government contracts contain certain terms and conditions, including termination provisions, that subject BioCryst to additional risks; the FDA, EMA, PMDA or other applicable regulatory agency may require additional studies beyond the studies planned for product candidates, may not provide regulatory clearances which may result in delay of planned clinical trials, may impose certain restrictions, warnings, or other requirements on product candidates, may impose a clinical hold with respect to such product candidates, or may withhold market approval for product candidates; product candidates, if approved, may not achieve market acceptance; BioCryst’s ability to successfully commercialize its product candidates, manage its growth, and compete effectively; risks related to the international expansion of BioCryst’s business; and actual financial results may not be consistent with expectations, including that 2020 operating expenses and cash usage may not be within management's expected ranges.  Please refer to the documents BioCryst files periodically with the Securities and Exchange Commission, specifically BioCryst’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, all of which identify important factors that could cause the actual results to differ materially from those contained in BioCryst’s projections and forward-looking statements.

BCRXW

Contact:
John Bluth
+1 919 859 7910
jbluth@biocryst.com

BIOCRYST PHARMACEUTICALS, INC.
CONSOLIDATED FINANCIAL SUMMARY
(in thousands, except per share)

Statements of Operations (Unaudited)

		Three Months Ended								Nine Months Ended
		September 30,								September 30,
			2020				2019				2020				2019
Revenues:
Product sales	$		2,478		$		335		$		2,696		$		2,014
Royalty revenue			254				508				2,243				3,526
Collaborative and other research and development			3,370				932				8,857				3,570
Total revenues			6,102				1,775				13,796				9,110

Expenses:
Cost of product sales			1,517				-				1,517				1,399
Research and development			30,245				25,120				87,610				80,294
Selling, general and administrative			17,195				11,735				46,943				26,632
Royalty			9				18				78				131
Total operating expenses			48,966				36,873				136,148				108,456

Loss from operations			(42,864	)			(35,098	)			(122,352	)			(99,346	)

Interest and other income and expense			(312	)			402				8,892				1,545
Interest expense			(2,927	)			(3,044	)			(8,892	)			(8,805	)
(Loss) gain on foreign currency derivative			(12	)			148				31				331

Net loss	$		(46,115	)	$		(37,592	)	$		(122,321	)	$		(106,275	)

Basic and diluted net loss per common share	$		(0.26	)	$		(0.34	)	$		(0.75	)	$		(0.96	)

Weighted average shares outstanding			176,521				110,416				164,127				110,308




Balance Sheet Data (in thousands)
	September 30, 2020								December 31, 2019
	(Unaudited)								(Note 1)
Cash, cash equivalents and investments		$	146,321							$	136,226
Restricted cash			2,213								1,551
Receivables from collaborations			5,422								22,146
Total assets			176,226								175,282
Non-recourse notes payable			29,890								29,561
Senior credit facility			46,041								50,309
Accumulated deficit			(962,949			)					(840,628			)
Stockholders’ equity			33,637								38,252
Shares of common stock outstanding			176,566								154,082

Note 1: Derived from audited financial statements.

EX-101.SCH 3 gnw-20190101.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 gnw-20190101_def.xml XBRL DEFINITION FILE EX-101.LAB 5 gnw-20190101_lab.xml XBRL LABEL FILE Class of Stock [Axis] Common Class A [Member] Preferred Class A [Member] Statement [Table] Statement [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 gnw-20190101_pre.xml XBRL PRESENTATION FILE XML 7 f8k_110520_htm.xml IDEA: XBRL DOCUMENT 0000882796 2020-11-05 2020-11-05 iso4217:USD shares iso4217:USD shares 0000882796 false 8-K 2020-11-05 BioCryst Pharmaceuticals, Inc. DE 000-23186 62-1413174 4505 Emperor Blvd., Suite 200 Durham NC 27703 919 859-1302 false false false false Common Stock BCRX NASDAQ false XML 8 R1.htm IDEA: XBRL DOCUMENT

Cover	Nov. 05, 2020
Document Type	8-K
Amendment Flag	false
Document Period End Date	Nov. 05, 2020
Entity File Number	000-23186
Entity Registrant Name	BioCryst Pharmaceuticals, Inc.
Entity Central Index Key	0000882796
Entity Tax Identification Number	62-1413174
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	4505 Emperor Blvd., Suite 200
Entity Address, City or Town	Durham
Entity Address, State or Province	NC
Entity Address, Postal Zip Code	27703
City Area Code	919
Local Phone Number	859-1302
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock
Trading Symbol	BCRX
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false

EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( (,Y95$'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " "#.6515K^A.N\ K @ $0 &1O8U!R;W!S+V-O&ULS9+/ M:L,P#(=?9?B>R$[W!TSJR\9.&PQ6V-C-V&IK&L?&UDCZ]G.R-F5L#["CI9\_ M?0*U)DH3$KZD$#&1PWPU^J[/TL0UVQ-%"9#-'KW.=4GTI;D-R6LJS[2#J,U! M[Q :SF_!(VFK2<,$K.)"9*JU1IJ$FD(ZX:U9\/$S=3/,&L ./?:40=0"F)HF MQN/8M7 !3##"Y/-W >U"G*M_8N<.L%-RS&Y)#<-0#ZLY5W80\/[\]#JO6[D^ MD^X-EE_923I&7+/SY+?5_AO@!02P,$% @ @SEE49E&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M M3A^%$5B-;'EDD81_OTV23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R M> +]O6N[!3+ MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,! M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2 MBW A(5M>5 TR M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$ MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7K;YH] M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZKR2.FJW"$2M"/F(9 M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+ MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+ M.7\N?<^E[[GT/:'2MSAD6R4)RU3393>* M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.WF)&Y M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_# M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0 MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYNTB42%(JP# 4A M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.' MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_ M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]! MU4#E/]O4#6CV#30,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04 M" "#.65121V"@A,$ #/#P & 'AL+W=OG;OEO:7B4ZBW= QW M JDBIN%4[>PT49SY>5 4VJ[C=.V(B=@:#_-K*S4>RDR'(N8K1=(LBI@Z3WDH MCR.+6N\77L5NK\T%>SQ,V(ZON?XM62DXLPL57T0\3H6,B>+!R)K0CU.W90+R M)WX7_)C>'!,SE*V4;^;DQ1]9CB'B(?>TD6#P=^ S'H9&"3C^NHI:Q3M-X.WQ MN_IS/G@8S):E?";#;\+7^Y'5MXC/ Y:%^E4>?^'7 76,GB?#-/\EQ\NS[;9% MO"S5,KH& T$DXLL_.UT3<1/0HG<"W&N FW-?7I13SIEFXZ&21Z+,TZ!F#O*A MYM$ )V)3E;56<%= G![/Y(&KH:U!RERPO6O8]!+FW@E;RD.3.)TGXCJN\\]P M&P@*#+? <'.]UAV]N?0RJ+4FFW/"JW#P\'[C$P+1*B!:J,H$"/R0\CV#;]WCF18>E/.)O,1>$P'M%:"]1T!G4%;%0E#U^8E\XN(,";_ ('M1 MJD2JG.R)K#5\#$0J,I,9I!.R*OW*FN/B\P5"2)W20)U'&">^KW@*$^9Z0#[# M<^1K7 E6(]GN.!VRB!*N8)#3\. W8="9@$%#L\6@;UR?_B?HF3F#EVWD,:X$ MQN7FF=JS"",K&P'%K?Q[LJ+8*R4/(O:J\XEK+F<86MD>*.[OWZ.M9*KA6_Y3 M)'=G8(VBV^LY+8RM;!D4=_J\@!-8E]U'P04&=("!E V"XN[^68)O@HW*&.L0 M-2+]SJ!!6XZ+$94M@N+>_DT)K7D,B8FB++[Z6UI)A0O5]7=:-@.*>_A:AL(3 M6L0[\@6FMQ(LK.3!56IYRBY <=->*=[P(#T_8DREF[L/N?DBXFIGLO0S*.B]<8F$Q=7U^Y_+?_MF M>V:VNE^8>6-*0AZ D-/L@1FJR^[Q&PO,]54'BO>OC 7M,XUQ MBJ.'KF6]=<#K/BQ2DJ6GTQU37&A:9'I0]PI[4IE!8TY/E!598_3.O*:1\*5< M ;EPF=-/7(K2B;F6*R&G2*>!J(PTCJ"W CE- M,_Q70247"YZ"BAC0LDBQWB MLUS*GR56U'LHI-P,IC02168Y(CA][\%UJ'V0??-/LL2*B\&/@]^-GO&/P2 \ M.&C$...QV?K?4D]NJW-KY?1!BE8KB'O_ZX9%QM=UI#-.//EN85(J3X"CY (. M175D?CINSS#B.DUC<]MS^M_S'SRWH,%Q>33M1__WCMDRBX>!OQKWC27A6LGI MMW!;R=T#*0@%=:*N0;^8>B^/O/37X96^KZ^AX8/$\Y;,Z1Y_A5H,ZMU6 M]1"^RU*UQU_"WYW-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO M8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0 ( (,Y95&JQ"(6 M,P$ "(" / >&PO=V]R:V)O;VLN>&ULC5'1;L(P#/R5*A^P%K0A#5%> M0-N0I@V-B??0NM0BB2O'A8VOG]NJ&M)>]I31=B;FJ1 M9IZFL:C!VWA'#02=5,3>BD(^IK%AL&6L <2[=)IEL]1;#&:Y&+6VG-X"$B@$ M*2C9$7N$2_R==S Y8\0#.I3OW/1W!R;Q&-#C%B/%*0:S;%4S. MY68R#/; @L4?>M>9_+2'V#-B#Q]6C>1FEJE@A1REW^CUK7H\@RX/J!5Z0B? M:ROPS-0V&(Z=C*9(;V+T/8SG4.*<_U,C5146L*:B]1!DZ)'!=09#K+&))@G6 M0VY6= ;N\N@#FW+()FKJIBF>HPYX4P[V1D\E5!B@?%.9J+SV4VPYZ8Y>9WK_ M,'G4'EKG5LJ]AU>RY1AQ_)[E#U!+ P04 " "#.651)!Z;HJT #X 0 M&@ 'AL+U]R96QS+W=O[IFBG#S^0W1UW6E\ M./VR./ /,+Q=Z*E%9"E*%1KD3,)HMC;!4N++3):BJ#(9BBJ6<%H@XLD@;6E6 M?;!/3K3G>1,)KM\,<'AT_@%02P,$% @ @SEE4660>9(9 0 MSP, !, !;0V]N=&5N=%]4>7!E&ULK9--3L,P$(6O$F5;)2XL6*"F M&V +77 !8T\:J_Z39UK2VS-.VDJ@$A6%3:QXWKS/GI>LWH\1L.B=]=B4'5%\ M% )5!TYB'2)XKK0A.4G\FK8B2K636Q#WR^6#4,$3>*HH>Y3KU3.T.EY M&TWP39G 8ED\C<+,:DH9HS5*$M?%P>L?E.I$J+EST&!G(BY84(JKA%SY'7#J M>SM 2D9#L9&)7J5CE>BM0#I:P'K:XLH90]L:!3JHO>.6&F,"J;$#(&?KT70Q M32:>,(S/N]G\P68*R,I-"A$YL01_QYTCR=U59"-(9*:O>"&R]>S[04Y;@[Z1 MS>/]#&DWY(%B6.;/^'O&%_\;SO$1PNZ_/[&\UDX:?^:+X3]>?P%02P$"% ,4 M " "#.651!T%-8H$ "Q $ @ $ 9&]C4')O M<',O87!P+GAM;%!+ 0(4 Q0 ( (,Y95%6OZ$Z[P "L" 1 M " :\ !D;V-0&UL4$L! A0#% @ @SEE44D=@H(3! SP\ !@ ("! M#@@ 'AL+W=O7!E&UL4$L%!@ ) D /@( ,@2 $ $! end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 1 95 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://globenewswire.com/role/Cover Cover Cover 1 false false All Reports Book All Reports f8k_110520.htm exh_991.htm gnw-20190101.xsd gnw-20190101_def.xml gnw-20190101_lab.xml gnw-20190101_pre.xml http://fasb.org/us-gaap/2019-01-31 http://xbrl.sec.gov/dei/2019-01-31 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "f8k_110520.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "local": [ "gnw-20190101_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "f8k_110520.htm" ] }, "labelLink": { "local": [ "gnw-20190101_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "gnw-20190101_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "gnw-20190101.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 63, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "gnw", "nsuri": "http://globenewswire.com/20190101", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "f8k_110520.htm", "contextRef": "Form8K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://globenewswire.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "f8k_110520.htm", "contextRef": "Form8K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r13" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The start date of the period covered in the document, in CCYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r9" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r12" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r18" ], "lang": { "en-US": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-US": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r17" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_CommonClassAMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Common Class A [Member]" } } }, "localname": "CommonClassAMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredClassAMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Preferred Class A [Member]" } } }, "localname": "PreferredClassAMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "stringItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r11": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r12": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1-" }, "r13": { "Name": "Forms 10-K, 20-F, 40-F", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d-1" }, "r14": { "Name": "Forms 20-F, 40-F", "Number": "249", "Publisher": "SEC", "Section": "220 and 240", "Subsection": "f" }, "r15": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r18": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-13" } }, "version": "2.1" } ZIP 15 0001171843-20-007628-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001171843-20-007628-xbrl.zip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